Tag:

bapineuzumab

Latest Headlines

Latest Headlines

Elan deal rumors fly; investors not enthused

FiercePharma | January 20, 2009
No sooner did Elan announce that it was evaluating its " strategic alternatives " than rumors began moving markets. The Danish pharma Lundbeck quickly arose as a possible suitor, on the flimsy evidence

Elan triggers strategic review, spurring merger buzz

FierceBiotech | January 13, 2009
Hit by harsh criticism of its handling of Tysabri and disappointing results on its experimental Alzheimer's drug, Ireland's Elan has initiated a strategic review that may lead straight to a sale or

Elan shareholders file lawsuit

FierceBiotech | October 15, 2008
Elan shareholders have filed a class action suit against the company. The biotech is being accused of making false and misleading statements regarding the development of the Alzheimer's drug

Alzheimer's drug results boost Elan, Wyeth

FierceBiotech | June 17, 2008
Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical
Related Tags

bapineuzumab Press Releases

  • Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease
  • Elan Announces Johnson & Johnson Release of Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) In Mild to Moderate Alzheimer’s Disease
  • Elan Announces Pfizer’s Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials
  • Elan Announces Pfizer’s Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials
  • Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab Phase 3 Program
Press Releases
  • Study Demonstrates Radioembolization Using SIR-Spheres Significantly Improves Overall Survival for Patients With Inoperable Colorectal Cancer
  • Study Demonstrates Radioembolization Using SIR-Spheres Significantly Improves Overall Survival for Patients With Inoperable Colorectal Cancer
  • Catalent Pharma Solutions Announces Launch of Catalent Applied Drug Delivery Institute
  • WuXi AppTec Hosts Global Monoclonal Antibody Summit, Opens First cGMP Biologics Facility in China
  • National Association of Dental Laboratories Legal Analysis Determines that the IRS proposed rule will not subject most products made by domestic dental laboratories to the new federal Medical Device Excise Tax
  • More Press Releases
Featured Jobs
  • Analytical Scientist Job
    Yoh - Emeryville, CA, USA
  • Principal Scientist, Analytical RD – Biologics Job
    Celgene Corporation - Summit, NJ, US
  • Statistician - Permanent Job
    Yoh - Tannersville, PA, USA
  • Scientist - Analytical Chemist Job
    Yoh - Swiftwater, PA, USA
  • Drug Safety Scientist Job
    Yoh - Parsippany-Troy Hills, NJ, USA
Sponsored Links